Long-Lasting HIV Prevention Drug Could Be Game Changer–But Who Will Pay?

August 5, 2022

(Nature) – An injectable drug that protects people at high risk of HIV infection has been recommended for use by the World Health Organization (WHO). Cabotegravir (also known as CAB-LA), which is given every two months, was initially approved by the United States Food and Drug Administration in December 2021. Cabotegravir is currently manufactured by ViiV Healthcare, a UK-based company jointly owned by GSK in London, Pfizer in New York City and Shionogi in Osaka, Japan. On 28 July, the day that the WHO issued its recommendation, ViiV announced a voluntary licensing agreement in which up to three other companies would be allowed to produce and supply generic versions of the drug; these would be intended for use in 90 of the world’s lowest-income countries, where the majority of new HIV cases occur. (Read More)